Tag: directors

SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on June 10, 2025, the company granted inducement awards to seventeen new employees. The grants were made pursuant to Nurix’s 2024 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).

NORTH LIBERTY, Iowa, June 13, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Heartland Express, Inc. (Nasdaq: HTLD) announced today the declaration of a regular quarterly cash dividend. The $0.02 per share dividend will be paid on July 3, 2025, to shareholders of record at the close of business on June 23, 2025. We currently estimate that a total of $1.6 million will be paid on the Company's approximate seventy-eight million shares of common stock. This is the Company's eighty-eighth consecutive quarterly cash dividend. With the payment of this dividend, the Company will have paid a total of $558.3 million in cash dividends, including four special dividends since the dividend program was implemented in the third quarter of 2003.

WINNIPEG, Manitoba, June 13, 2025 (GLOBE NEWSWIRE) -- (TSX Symbol: NWC): The North West Company Inc. (the “Company” or “North West”) today announced that shareholders voted in favour of all items of business put forth by the Company at its annual general meeting of shareholders held on June 11, 2025, including the election of all the nominee directors listed in the Notice of Meeting and Management Information Circular dated April 9, 2025:

VANCOUVER, British Columbia, June 13, 2025 (GLOBE NEWSWIRE) -- 1317229 B.C. Ltd. (“131” or the “Company”) and Launchit Solutions Inc. (“Launchit”) are pleased to announce that the Company, Launchit and 1001240330 Ontario Inc. (“Subco”), a wholly-owned subsidiary of the Company, have entered into a business combination agreement dated June 12, 2025 (the “Business Combination Agreement”) pursuant to which the Company will acquire Launchit by way of a three-cornered amalgamation, which will result in the reverse takeover of 131 by Launchit (the “Proposed Transaction”). Upon completion of the Proposed Transaction, the Company will continue to carry on the business of Launchit (thereafter referred to as the “Resulting Issuer”).

SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE^® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors.

Millicom (Tigo) Announces Partial Closing of Infrastructure Deal with SBA and Intention to Declare a Special Dividend of $2.50 per Share Representing Around 45% of the Proceeds